Effects of Combined Simultaneous and Sequential Endostar and Cisplatin Treatment in a Mice Model of Gastric Cancer Peritoneal Metastases. (19th January 2017)

• Record Type: Journal Article
• Authors: Jia, Lin; Ren, Shuguang; Li, Tao; Wu, Jianing; Zhou, Xinliang; Zhang, Yan; Wu, Jianhua; Liu, Wei
• Other Names: Honore Charles Academic Editor.
• Is Part Of: Gastroenterology research and practice. Volume 2017(2017)
• Publication Date: 2017-01-19
• Subjects: Gastroenterology -- Periodicals; Digestive organs -- Diseases -- Periodicals; 616.33005
• DOI: 10.1155/2017/2920384
• Languages: English
• ISSNs: 1687-6121

Abstract

Abstract : Objective . Aimed to study the effects of endostar and cisplatin using an in vivo imaging system (IVIS) in a model of peritoneal metastasis of gastric cancer. Methods . NUGC-4 gastric cancer cells transfected with luciferase gene (NUGC-4-Luc) were injected i.p. into nude mice. One week later, mice were randomly injected i.p.: group 1, cisplatin (d1–3) + endostar (d4–7); group 2, endostar (d1–4) + cisplatin (d5–7); group 3, endostar + cisplatin d1, 4, and 7; group 4, saline for two weeks. One week after the final administration, mice were sacrificed. Bioluminescent data, microvessel density (MVD), and lymphatic vessel density (LVD) were analyzed. Results . Among the four groups, there were no significant differences in the weights and in the number of cancer cell photons on days 1 and 8 (P > 0.05 ). On day 15, the numbers in groups 3 and 1 were less than that in group 2 (P < 0.05 ). On day 21, group 3 was significantly less than group 2 (P < 0.05 ). MVD of group 4 was less than that of groups 1 and 2 (P < 0.01 ). There was no significant difference between groups 2 and 3 (P > 0.05 ) or in LVD number among the four groups (P > 0.05 ). Conclusions . IVIS® was more useful than weight, volume of ascites, and number of peritoneal nodules. The simultaneous group was superior to sequential groups in killing cancer cells and inhibiting vascular endothelium. Cisplatin-endostar was superior to endostar-cisplatin in killing cancer cells, while the latter in inhibiting peritoneal vascular endothelium.